Pharmacokinetics of a valpromide isomer, valnoctamide, in healthy subjects

M. Bialer, A. Haj-Yehia, N. Barzaghi, F. Pisani, E. Perucca

Research output: Contribution to journalArticlepeer-review


The pharmacokinetics of a single 400 mg oral dose of valnoctamide (VCD) has been investigated in seven healthy, adult, male volunteers. VCD was not biotransformed rapidly to its corresponding acid valnoctic acid (VCA), unlike its isomer valpromide (VPD). It had a mean residence time of 13.2 h and a terminal half-life of 9.3 h. Throughout the study, only low plasma levels of VCA could be detected. Thus, unlike VPD, which is a prodrug of the corresponding acid, (valproic acid, VPA). VCD appears to act as a drug in its own right, and it does not undergo similar hydrolysis. The pharmacokinetic difference may account for the different pharmacological activities of the two isomers.

Original languageEnglish
Pages (from-to)289-291
Number of pages3
JournalEuropean Journal of Clinical Pharmacology
Issue number3
Publication statusPublished - Mar 1990


  • healthy subjects
  • pharmacokinetics
  • tranquiliser
  • valnoctamide
  • valproic acid
  • valpromide

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Pharmacology (medical)


Dive into the research topics of 'Pharmacokinetics of a valpromide isomer, valnoctamide, in healthy subjects'. Together they form a unique fingerprint.

Cite this